Does a higher arachidonic acid to EPA ratio indicate greater inflammatory mediator pressure?

The cellular ratio of arachidonic acid (AA) to eicosapentaenoic acid (EPA) is a fundamental biomarker of systemic inflammatory tone, reflecting a direct biochemical tug-of-war for enzymatic processing.

Enzymatic competition and kinetics

• Cyclooxygenase competition: AA and EPA compete directly for the catalytic sites of COX-1 and COX-2. While both fatty acids exhibit similar binding affinities for COX-2 ($K_m \approx K_d \approx 5\text{--}10 \ \mu\text{M}$), EPA has a maximum reaction rate ($V_{max}$) of less than 20% of AA at COX-1, making EPA a highly effective competitive inhibitor of AA-derived prostanoid synthesis.
• Lipoxygenase dynamics: Although LOX enzymes (5-LOX, 12-LOX, and 15-LOX) preferentially metabolize AA, high concentrations of EPA act as a competitive substrate, raising the apparent $K_m$ for AA and displacing it from these pathways to reduce pro-inflammatory series-4 leukotriene production.

Downstream mediator pressure

• Synthesis shift: A high AA:EPA ratio favors the generation of pro-inflammatory series-2 prostaglandins (PGE2) and series-4 leukotrienes (LTB4) over EPA-derived specialized pro-resolving mediators (SPMs), such as E-series resolvins (RvE1).
• Receptor-level competition: The balance between these lipids directly dictates downstream signaling. RvE1 and LTB4 compete for binding at the shared, high-affinity BLT1 receptor; RvE1 occupancy shifts the cellular program toward active resolution, whereas LTB4 occupancy promotes sustained inflammation.
• Clinical associations: Elevated systemic AA:EPA ratios are strongly correlated with increased biomarkers of inflammation, such as IL-6 and C-reactive protein (CRP), and poorer cardiovascular outcomes.

Bottom line

• An elevated AA:EPA ratio biochemically favors pro-inflammatory eicosanoid production over anti-inflammatory resolution. This is driven by direct competition for COX and LOX enzyme active sites and receptor-level antagonism at the shared BLT1 receptor, resulting in heightened systemic inflammatory pressure.